Nope I'm not shorting anything, I've been strictly a long player in biotech, and have worked in biotech industry startups since '85 have watched the industry as a whole fairly closely. I believe in investing in what I understand. I just don't like to see people get too carried away with venture capital quality stocks, and AIMM definitely qualifies as this, unless they are diversified as it hurts the reputation of the entire biotech sector when they tank, let alone the investors. IMO, anyone who has more than about 5 or 10% of their risk capital in a stock like AIMM is way over-exposed.
I also would love to see the RA drug work as my mother-in-law has a serious 25 year old case of RA and was we were all very disappointed to see it fail.
I first got interested in this thread when I was asked by someone to assess Organ's first post about his inside info that the clinical had failed, (which I believed, but still wouldn't touch shorting the stock as I didn't think it was an ethical way to invest) and then after the failure looked at it as a study in biotech stocks. Check the INCY thread for the cryptic discussions of the Organ. I also gave Organ a lot of crap after the failure, and really do hope the SEC goes after him to get to his sources! Funny how the Organ doesn't post here anymore. It was tempting to turn him in myself, the SEC pays a 10% reward for such info, but I didn't want to bother with it either and get my hands dirty over it. If no one has done it yet, the profit on that might be a better play than AIMM is these days. As a scientist, I have personally believed in the theory of oral tolerance for quite a few years and am disappointed that AIMM has been unable to definitively prove it. I still think that the theory is valid, but that clinically proving it is not easy or straightforward. As far as profits go, I'm doing fine lately, and was up 100% on equity in the month of May. Had another nice day today too. So, mellow out Joe and don't be so bitter, I had nothing to do with AIMMs failures to date and have no vested interest in how the stock does.
Rman |
